Nordic EMBL Partnership for Molecular Medicine
Partners: EMBL; NCMM-University of Oslo, Norway; MIMS-Umeå University, Sweden; FIMM-University of Helsinki, Finland; DANDRITE-Aarhus University
The Nordic EMBL Partnership for Molecular Medicine was initiated in 2007 between the University of Oslo, Umeå University, University of Helsinki and EMBL. As a result, three nodes were established in Norway, Sweden and Finland, each of which complements the research expertise of the other partners and, working closely with EMBL, aims to rise to challenges in biomedicine and to foster industry collaborations. In March 2013 the Nordic EMBL Partnership for Molecular Medicine celebrated two important milestones: the renewal of the partnership agreement for an extended period of 10 years, and the expansion of the Nordic EMBL network with the official opening of the Danish Research Institute of Translational Neuroscience (DANDRITE) at Aarhus University, which became its Danish node.
The partnership facilitates scientific collaboration and access to scientific infrastructure, including databases, facilities and instrumentation, as well as services and training activities provided by the partners. In addition to their partnership with EMBL, the individual Nordic research centres engage in collaborations with other national partners, including research and public health institutes, hospitals and research councils, with the aim of establishing an extensive Nordic network for molecular medicine.
Centre for Molecular Medicine Norway (NCMM)
The Norwegian Node of the Nordic EMBL Partnership for Molecular Medicine is the Centre for Molecular Medicine Norway (NCMM) and is headed by Prof. Kjetil Taskén. It is hosted by the University of Oslo (UoO) in partnership with the Regional Health Authority SouthEast, and with links to the other Universities and Regional Health Authorities in Norway.
The University of Oslo (UoO) is the largest research institution in Norway with more than 6 000 staff and 33 000 students. UoO has extensive research activity in molecular medicine, clinical medicine and molecular life sciences relevant to the operation of the Nordic EMBL Partnership for Molecular Medicine.
On the European level EMBL and NCMM are jointly involved in the EU-OPENSCREEN project, part of European Strategy Forum on Research Infrastructures (ESFRI).
Laboratory for Molecular Infection Medicine Sweden (MIMS)
The Swedish Node of the Nordic EMBL Partnership for Molecular Medicine is the Laboratory for Molecular Infection Medicine Sweden (MIMS). MIMS is headed by Prof. Bernt Eric Uhlin and is established within the Umeå Centre for Microbial Research (UCMR). It is affiliated with both the Faculty of Medicine and the Faculty of Science and Technology and closely connected to the university hospital (Norrlands University Hospital).
UCMR consists of researchers active in the fields of molecular and clinical microbiology, molecular biology, chemistry, and physics and the research groups include a pronounced international profile with many guest researchers and graduate students, as well as faculty members, from other countries. The groups work in modern laboratories with well-equipped common facilities creating a framework for a creative and highly interactive environment.
Support for MIMS is granted by the Swedish Research Council with the aim to strengthen Swedish research and enhance the dynamics in the field of molecular medicine, partly by promoting the career opportunities for young scientists.
Institute for Molecular Medicine Finland (FIMM)
The Finnish Node of the Nordic EMBL Partnership for Molecular Medicine is the Institute for Molecular Medicine Finland (FIMM) headed by Prof. Olli Kallioniemi. FIMM is a joint venture of the University of Helsinki, the Hospital District of Helsinki and Uusimaa (HUS), and the National Public Health Institute (KTL).
The aim of FIMM is to merge the strategic resources and research in the field of molecular medicine, genetics and epidemiology in Finland, capitalising on the Finnish genetic-epidemiological and clinical materials and registers, as well as to develop into a high-profile international institute of translational research. The mission of the Institute is to advance new fundamental understanding of the molecular, cellular and etiological basis of human diseases. This understanding will lead to improved means of diagnostics and the treatment and prevention of common health problems.
Danish Research Institute of Translational Neuroscience (DANDRITE)
The Danish Node of the Nordic EMBL Partnership for Molecular Medicine is the Danish Research Institute of Translational Neuroscience (DANDRITE), headed by Prof. Poul Nissen.
DANDRITE is hosted by Aarhus University (AU). It is affiliated with both the Faculty of Health and the Faculty of Science and Technology, and is connected to the Aarhus University Hospital. DANDRITE will focus on conducting research in the field of neuroscience. DANDRITE is embedded in a research infrastructure with state of the art facilities and approaches in e.g. structural and functional studies of membrane proteins in the nervous system at a molecular, cellular and tissue level; biophysical methodologies; transgenic and gene modified animal models; cellular and clinical imaging; nanoscience; structure-based; genetics and computer-assisted drug discovery.
The establishment of the Danish node was made possible through the Lundbeck Foundation, one of the largest private contributors to natural science research in Denmark, which funds the new centre jointly with Aarhus University.